Hepatitis C Virus (HCV) Gensosure® NS3/4A Provides Comprehensive Resistance Data for New HCV Protease Inhibitors

  • Analyzes the genetic sequence for the nonstructural proteins NS3 and NS4A of HCV genotypes 1a and 1b
  • Identifies the Q80K polymorphism
  • Detects mutations in NS3 and NS4A and identifies drug-resistant variants for protease inhibitors grazoprevir, paritaprevir​, and simeprevir.
  • Sensitivity to detect minor variant levels as low as 10% provides a detailed understanding of the patient’s viral population for informed treatment decisions
Test Name Hepatitis C Virus (HCV) GenoSure® NS3/4A
LabCorp Test Number 550540
Limitation For patients with HCV genotype (subtype) 1a or 1b and a viral load ≥ 2000 IU/mL
Specimen Collection 3 mL plasma, EDTA or PPT tube, shipped frozen
Turnaround Time 7 to 10 days

Pharmaceutical companies are using our HCV genotypic and phenotypic resistance assays to support all phases of research and clinical development for several new HCV compounds. As more new compounds reach the clinic, Monogram's assays will continue to provide useful information for patient management. For more information about our full line of HIV, HCV, or pharmaceutical services, visit our Pharma Collaborations page.